Daewon Pharmaceutical said Monday that it would make a contingency shipment of Freefol-MCT (Middle Chain Triglycerides) injection (Ingredient: propofol), an intravenous anesthetic used to treat Covid-19, to Luxembourg.

The company received an urgent request from the head of the Luxembourg Trade and Investment Office in Seoul and signed the export contract. Both the Luxembourg Ministry of Health in April and the Korean Ministry of Food and Drug Safety approved the deal.

Daewon Pharmaceutical’s Freefol-MCT injection

Daewon began to ship the first batch by air on May 9 and plans to discuss gradually additional shipments.

Propofol is general anesthesia administered through a vein. The product is well known for its sedative effect in relieving respiratory difficulties of severe patients who are to receive operation.

Daewon’s Freefol-MCT has improved side effects, including pain, inflammation, and dyslipidemia, of the existing propofol formulation containing LCT (Long Chain Triglyceride) formulations.

The company’s vial product has enhanced safety and convenience as it is more durable than ampoules and can prevent glass fragments from mixing with the drug, Daewon said.

“The demand for propofol is rapidly increasing as the product is being increasingly used to treat the Covid-19 patients in Europe,” a company official said. “The company is discussing with other nations, including Sweden and Israel, as they also have requested for the export of Freefol-MCT.

shim531@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>